Suicidal thoughts remain one of the most concerning symptoms in mental health, and treatments that address them directly are still limited. Researchers are now turning to the brain itself to understand what drives these thoughts and how to predict when treatments will work. A recent systematic review gathered new evidence on neurophysiological biomarkers of suicidal ideation, offering a clearer picture of the brain regions that may shape treatment response.
The review examined 24 clinical studies published mostly within the past five years. While many studies used different designs and measurement tools, making firm conclusions challenging, the overall message was encouraging. Several brain areas, especially the anterior cingulate cortex and prefrontal cortex, appear to play key roles in how suicidal thinking changes during treatment. These findings could help clinicians personalize care and guide future trials.
Why The Anterior Cingulate Cortex Matters In Suicidal Ideation
One of the strongest patterns across the studies involved the anterior cingulate cortex, a region known for regulating emotional conflict, decision making, and internal monitoring. The review found that intravenous ketamine often produces fast reductions in suicidal thinking, and these improvements were linked to changes in this brain region.
Interestingly, these ketamine related ACC changes were not seen in patients who received oral ketamine. This difference may help explain why IV ketamine tends to produce stronger and faster anti suicidal effects compared to oral forms. The ACC may be especially responsive to the rapid neurochemical shifts triggered by infusion based treatment.
This insight highlights a larger theme in the study of neurophysiological biomarkers of suicidal ideation. Fast acting treatments may rely on circuits involved in emotional regulation, and the ACC could serve as a measurable indicator of whether a treatment is likely to work.
The Role Of the Prefrontal Cortex In Seizure Based Therapies
Electroconvulsive therapy and magnetic seizure therapy were also included in the systematic review. Both treatments have shown meaningful reductions in suicidal ideation in prior clinical work. According to the findings, improvements in suicidal thinking after these treatments were linked to activity in the prefrontal cortex. This is an area deeply involved in planning, impulse regulation, and evaluating consequences.
Unlike ketamine, which tends to produce rapid but temporary benefits, seizure based therapies often lead to more sustained improvements. The review suggests this difference may come from how each treatment shifts the balance of activity across the ACC and PFC. Tracking PFC signals over time may help clinicians understand who benefits most from ECT or MST and whether maintenance treatments are needed.
Why Biomarkers Matter For The Future Of Suicide Prevention
Although the review highlighted promising patterns, it also emphasized the need for stronger, more consistent research methods. Many of the included studies used small samples, non randomized designs, or incomplete treatment protocols. Suicidal ideation is a complex symptom, and measuring it requires validated, specific tools that many studies did not fully use.
Even with these challenges, the review points to a clear opportunity. Identifying reliable brain based markers could transform how clinicians assess risk, choose treatments, and track progress. For researchers designing new interventions, incorporating biomarkers from the start could improve trial quality and accelerate discovery.
Understanding the neurophysiological biomarkers of suicidal ideation may help shift the field from reactive care to proactive, precision based approaches. With better markers, treatments like ketamine, seizure therapies, and future neuromodulation strategies could be tailored more effectively to the people who need them most.
Citations
- Stapper N, Benster L, Menon S, et al. Neurophysiological biomarkers of treatment response in suicidal ideation. Transl Psychiatry. 2025. https://doi.org/10.1038/s41398-025-03477-2
- Hom MA, Bowers EM, Björgvinsson T, Beard C. Comparing treatment outcomes among individuals with and without recent suicidal ideation. J Clin Psychol. 2021. https://pubmed.ncbi.nlm.nih.gov/33135732/